+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease

Journal of Clinical Oncology 6(6): 1047-1052

Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease

Between 1968 and 1983, 135 patients with pathologic stage (PS) I and II Hodgkin's disease were treated with extended mantle radiation technique (EMRT) at Michael Reese Hospital and the University of Chicago Center for Radiation Therapy. EMRT combines both standard mantle and para-aorta fields (M-PA) in one port. Actuarial disease-free survival at 5 and 10 years was 82.5%. Actuarial overall survival was 96% and 83% at 5 and 10 years, respectively. Acute complications were evaluated in 112 patients available for analysis. Severe nausea and vomiting occurred in 13%, weight loss of greater than 10% of body weight in 19%, and acute hematologic toxicity in 4% of patients. Bone marrow suppression was transient and did not interfere with subsequent delivery of salvage treatment with either chemotherapy or radiation therapy in 22 patients who relapsed. The cost of EMRT is 40% lower than the cost of treatment with M-PA. The median treatment time was 38 days, 33% less than the 56 days for M-PA field assuming no interruptions. These results suggest that the EMT is a safe and effective treatment tolerated by most patients. The advantages of this method are eliminating the possibility of technical error of matching between mantle and para-aortic field, decreasing overall treatment time, and reducing the cost.

(PDF same-day service: $19.90)

Accession: 005432623

PMID: 3373259

DOI: 10.1200/jco.1988.6.6.1047

Related references

Extended mantle radiation therapy for pathologic stage i and ii hodgkins disease. International Journal of Radiation Oncology*Biology*Physics 13(supp-S1): 122-0, 1987

Long-term results of 60 patients with pathologic stage I and IIA Hodgkin's disease treated with exclusive mantle radiation therapy. European Journal of Haematology 63(2): 126-133, 1999

Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy. International Journal of Radiation Oncology, Biology, Physics 17(4): 761-766, 1989

Conservative surgery and radiation therapy for early stage breast cancer after previous mantle radiation for Hodgkin's disease. British Journal of Radiology 73(872): 905-906, 2000

Supradiaphragmatic early stage Hodgkin's disease: does mantle radiation therapy still have a role?. Haematologica 81(2): 138-142, 1996

Mantle irradiation alone for pathologic Stage I and II Hodgkin's disease: Long-term follow-up and patterns of failure. International Journal of Radiation Oncology Biology Physics 50(4): 971-977, July 15, 2001

Hodgkin disease: clinical utility of CT in initial staging and treatment, and Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy. Investigative Radiology 24(10): 822-824, 1989

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leukemia & Lymphoma 46(11): 1561-1567, 2005

Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. Journal of Clinical Oncology 10(3): 378-382, 1992

Pulmonary reaction to upper mantle radiation therapy for Hodgkin's disease. Chest 75(6): 688-692, 1979